06.06.2025 11:23:07
|
Arvinas Announces Submission Of NDA With Its Partner Pfizer For Vepdegestrant
(RTTNews) - Arvinas (ARVN) announced the submission of a New Drug Application to the FDA with its partner Pfizer (PFE), for vepdegestrant for the treatment of patients with ER+/human epidermal growth factor receptor 2-negative ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. The submission is based on results from VERITAC-2, a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant.
Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Arvinas Inc Registered Shsmehr Nachrichten
30.04.25 |
Ausblick: Arvinas präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) | |
10.02.25 |
Ausblick: Arvinas zieht Bilanz zum abgelaufenen Quartal (finanzen.net) | |
29.10.24 |
Ausblick: Arvinas legt Quartalsergebnis vor (finanzen.net) |